...
首页> 外文期刊>European journal of pharmaceutical sciences >Dissolution enhancement of Deflazacort using hollow crystals prepared by antisolvent crystallization process
【24h】

Dissolution enhancement of Deflazacort using hollow crystals prepared by antisolvent crystallization process

机译:使用反溶剂结晶工艺制备的空心晶体增强Deflazacort的溶出度

获取原文
获取原文并翻译 | 示例

摘要

Deflazacort (DFZ), a derivate of prednisolone, is a poorly soluble drug which has been proposed to have major advantages over other corticosteroids. Poorly soluble drugs present limited bioavailability due to their low solubility and dissolution rate and several strategies have been developed in order to find ways to improve them. In general, pharmaceutical laboratories use a micronized process to reduce the particle size in order to increase the dissolution of the drugs. However, this process causes changes such as polymorphic transitions, particle agglomeration and a reduction in fluidity and wettability. These solid-state properties affect the dissolution behavior and stability performance of drugs. Crystallization techniques are widely used in the pharmaceutical industry and antisolvent crystallization has been used to obtain ultrafine particles. In this study, DFZ was investigated in terms of its antisolvent crystallization in different solvents and under various preparation conditions (methanol/water ratio, stirring and evaporation rate, etc.), in order to compare the physicochemical properties between crystallized samples and raw materials available on the Brazilian market with and without micronization. Crystalline structure, morphology, and particle size, and their correlation with the Intrinsic Dissolution Rate (IDR) and dissolution profile as relevant biopharmaceutical properties were studied. Crystallization conditions were achieved which provided crystalline samples of hollow-shaped crystals with internal channels, which increased the dissolution rate of DFZ. The antisolvent crystallization process allowed the formation of hollow crystals, which demonstrated a better dissolution profile than the raw material (crystalline and micronized), making this a promising technique as a crystallization strategy for improving the dissolution and thus the bioavailability of poorly soluble drugs.
机译:泼尼松龙的衍生物Deflazacort(DFZ)是一种难溶药物,已被提议具有比其他皮质类固醇更大的优势。难溶性药物由于其低溶解度和溶解速度而具有有限的生物利用度,因此已经开发了几种策略来寻找改善它们的方法。通常,制药实验室使用微粉化工艺来减小粒径,以增加药物的溶解度。然而,该过程引起变化,例如多晶型转变,颗粒团聚以及流动性和润湿性降低。这些固态特性会影响药物的溶解行为和稳定性。结晶技术已广泛用于制药工业,并且反溶剂结晶已用于获得超细颗粒。在这项研究中,研究了DFZ在不同溶剂中和在各种制备条件(甲醇/水比,搅拌和蒸发速率等)下的抗溶剂结晶性,以便比较结晶样品和可用原料之间的理化性质。在巴西市场上有无微粉化。研究了晶体结构,形态和粒径,以及它们与本征溶出度(IDR)和溶出曲线的相关性,作为相关的生物药物特性。达到的结晶条件为空心晶体的晶体样品提供了内部通道,从而增加了DFZ的溶解速率。抗溶剂结晶过程允许形成中空晶体,该中空晶体显示出比原料(晶体和微粉化)更好的溶出曲线,这使其成为一种有前景的技术,可作为改善溶出度,从而改善难溶性药物生物利用度的结晶策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号